UMIN-CTR Clinical Trial

Basic information
Official scientific title of the study	Clinical pharmacological study of TM5509 -Clinical pharmacological study in male mild obesity subjects (additional test)-
Title of the study (Brief title)	Clinical pharmacological study of TM5509 -Clinical pharmacological study in male mild obesity subjects (additional test)- (TM5509-7)
Region	Japan

Condition
Condition	Recover of hematogenesis after cord blood transplantation
Classification by specialty	Hematology and clinical oncology
Classification by malignancy	Others
Genomic information	YES

Objectives
Narrative objectives1	Primary objective Investigation for pharmacodynamics of TM5509 in Japanese male mild obesity subjects. Secondary objective Investigation for safety and pharmacokinetics of TM5509.
Basic objectives2	Pharmacodynamics
Basic objectives -Others
Trial characteristics_1	Exploratory
Trial characteristics_2
Developmental phase	Phase I

Assessment
Primary outcomes	Pharmacodynamics of TM5509
Key secondary outcomes	Safety and Pharmacokinetics of TM5509

Base
Study type	Interventional

Study design
Basic design	Cross-over
Randomization	Randomized
Randomization unit	Individual
Blinding	Single blind -participants are blinded
Control	Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms	2
Purpose of intervention	Treatment
Type of intervention	Medicine
Interventions/Control_1	step1 TM5509 (180mg, once a day for 3days) washout period more than 3weeks step2 placebo (once a day for 3days)
Interventions/Control_2	step1 placebo (once a day for 3days) washout period more than 3weeks step2 TM5509 (180mg, once a day for 3days)
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit	20 years-old <=
Age-upper limit	45 years-old >
Gender	Male
Key inclusion criteria	1. Male Japanese 2. From 20 years old to 45 years old at voluntary written consent 3. From 65.0 kg to 90.0 kg and from 25.0 to 30.0 of BMI at screening 4. More than 20ng/ml of total PAI-1 5. Voluntary written consent by themselves is given before screening
Key exclusion criteria	1. History of liver diseases, cardiovascular diseases, respiratory diseaases, gastroenteric diseases, kidney diseases, cerebralvascular diseases, cancer 2. Known hypersensitivity to some drugs and foods 3. More than grade 1 in liver function disorders 4. Treatment by other doctors (included supplement) within 14 days before screening 5. Treatment with any investigational compound within 120 days before screening 6. History of TM5509 administration 7. History of blood taken *>= 1200ml of all blood within 1 year before screening *>= 400ml of all blood with 84 days before screening *>= 200ml of all blood within 14 days before screening 8. Smoking status and treatment with anti-nicotine agents 9. Known active chronic hepatitis B or C, active syphilis and human immunodeficiency virus infection 10. Abuse of alcohol or drugs (included past history) 11. Bleeding, in the tendency to bleeding, and family history and past history of bleeding disorders 12. Somebody who are directed by principle investigator and employees in Hamamatsu University hospital 13. Any serious medical or psychiatric illness that could, in the opinion of the investigator, potentially interfere with the completion of treatment according to this protocol.
Target sample size	10

Research contact person
Name of lead principal investigator	Kazuo Umemura
Organization	Hamamatsu University Hospital
Division name	Center for clinical research
Address	1-20-1 Handayama Higashi-ku, Hamamatsu, Japan
TEL	053-434-6587
Email	umemura@hama-med.ac.jp

Public contact
Name of contact person	Kazuo Umemura
Organization	Hamamatsu University Hospital
Division name	Center for clinical research
Address	1-20-1 Handayama Higashi-ku, Hamamatsu, Japan
TEL	053-434-6587
Homepage URL	http://hama-ccr.jp/tr/
Email	umemura@hama-med.ac.jp

Sponsor
Institute	Tohoku university school of medicine, molecular medicine and therapy, Toshio Miyata
Institute
Department

Funding Source
Organization	ministry of health, labour and welfare
Organization
Division
Category of Funding Organization	Japanese Governmental office
Nationality of Funding Organization	Japan

Other related organizations
Co-sponsor
Name of secondary funｄer(s)

Secondary IDs
Secondary IDs	NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information	2016 Year 01 Month 08 Day

Progress
Recruitment status	Completed
Date of protocol fixation	2016 Year 01 Month 08 Day
Anticipated trial start date	2016 Year 01 Month 27 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Related information
URL releasing protocol
Publication of results	Unpublished
URL releasing results
Results
Other related information

Management information
Registered date	2015 Year 12 Month 25 Day
Last modified on	2016 Year 09 Month 28 Day

Link to view the page
URL(English)	https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023491